Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation and Depletion: 2012-2020

Historic Depreciation and Depletion for Ani Pharmaceuticals (ANIP) over the last 9 years, with Dec 2020 value amounting to $1.3 million.

  • Ani Pharmaceuticals' Depreciation and Depletion rose 8.33% to $1.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.9 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $7.4 million for FY2024, which is 1.33% down from last year.
  • According to the latest figures from Q4 2020, Ani Pharmaceuticals' Depreciation and Depletion is $1.3 million, which was up 8.33% from $1.2 million recorded in Q3 2020.
  • Ani Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $1.3 million during Q4 2020, with a 5-year trough of $200,000 in Q1 2016.
  • Over the past 3 years, Ani Pharmaceuticals' median Depreciation and Depletion value was $1.1 million (recorded in 2019), while the average stood at $966,667.
  • Data for Ani Pharmaceuticals' Depreciation and Depletion shows a peak YoY skyrocketed of 300.00% (in 2019) over the last 5 years.
  • Ani Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $200,000 in 2016, then spiked by 50.00% to $300,000 in 2017, then spiked by 166.67% to $800,000 in 2018, then surged by 50.00% to $1.2 million in 2019, then rose by 8.33% to $1.3 million in 2020.
  • Its Depreciation and Depletion was $1.3 million in Q4 2020, compared to $1.2 million in Q3 2020 and $1.2 million in Q2 2020.